Neurology. 2017 Feb 15. 

doi: 10.1212/WNL.0000000000003696. 

Imtiaz B¹, Tuppurainen M², Rikkonen T², Kivipelto M², Soininen H², Kröger H², Tolppanen AM².

Abstract

OBJECTIVE:

To explore the association between postmenopausal hormone therapy (HT) and Alzheimer disease (AD).

METHODS:

Twenty-year follow-up data from the Kuopio Osteoporosis Risk Factor and Prevention study cohort were used. Self-administered questionnaires were sent to all women aged 47-56 years, residing in Kuopio Province starting in 1989 until 2009, every 5th year. Register-based information on HT prescriptions was available since 1995. Probable AD cases, based on DSM-IV and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria, were identified from the special reimbursement register (1999-2009). The study population included 8,195 women (227 cases of incident AD).

RESULTS:

Postmenopausal estrogen use was not associated with AD risk in register-based or self-reported data (hazard ratio/95% confidence interval 0.92/0.68-1.2, 0.99/0.75-1.3, respectively). Long-term self-reported postmenopausal HT was associated with reduced AD risk (0.53/0.31-0.91). Similar results were obtained with any dementia diagnosis in the hospital discharge register as an outcome.

CONCLUSIONS:

Our results do not provide strong evidence for a protective association between postmenopausal HT use and AD or dementia, although we observed a reduced AD risk among those with long-term self-reported HT use.

資料來源：PubMed